AMPA receptor


Also found in: Wikipedia.

AMPA re·cep·tor

a type of glutamate receptor that participates in excitatory neurotransmission and also binds α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and acts as a cation channel.

AMPA receptor

A member of the ionotropic class of glutamate receptors (which includes NMDA and kainate receptors).

Functions
Mediate fast excitatory synaptic transmission in the CNS; play a key role in hippocampal synaptic long-term potentiation (LTP) and depression (LTD).

Structure
GluR1-4 subunits which assemble as homomers or heteromers to form functional AMPA receptors. The subunit composition determines the physiological properties of AMPA receptors: those with a GluR2 subunit have low permeability to Ca2+; those lacking a GluR2 subunit have high Ca2+ permeability.

AMPA receptor

Neurophysiology Any of a family of distinct ionotropic glutamate–excitatory post-synaptic receptors widely expressed in the CNS, which are the 1º memory receptors. See Excitatory amino acid receptor channel, Glutamate receptor.
References in periodicals archive ?
The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes.
With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes.
They used a chemical tag to watch how key "AMPA" receptors changed in the synapses and saw that synaptic enlargement and strengthening correlated with more AMPA receptor expression while shrinking and weakening correlated with less AMPA receptor expression.
Edonerpic maleate helps this process by facilitating the delivery of an important neurotransmitter receptor, called AMPA receptor, to the structures called synapses, which mediate information between neurons.
FYCOMPA, which is the first and only seizure medication that targets the AMPA receptor, was initially approved for adjunctive use in patients with POS and PGTC seizures, as a monotherapy use for the treatment of patients with POS as well as an oral suspension formulation.
The product, which is ready for phase 2b development, is an AMPA receptor potentiator, developed for treating cognitive impairment associated with schizophrenia.
Biogen (BIIB) announced an agreement to acquire from Pfizer (PFE) a Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia.
Target: PF-0495824, an AMPA receptor potentiator for cognitive impairment associated with schizophrenia
[36] found that the knockdown of NL1 in developing neurons in the optic tectum of Xenopus laevis tadpoles led to a decrease in synapse densities and AMPA receptor current frequency.
Since all three AEDs have an inhibiting effect on glutamatergic transmission via the AMPA receptor, it appears most promising for future research to focus on this mechanism [18].
GRIP1 can directly interact with and control kinesin heavy chains in dendrites as a motor for the AMPA receptor [15].
Abbreviations: PNS: peripheral nervous system; NMJ: neuromuscular junction; CNS: central nervous system; EM: electron microscopy; FIB-SEM: focused ion beam/scanning electron microscopy; GFP: green fluorescent protein; PSD: postsynaptic density; NMDA: N-methyl-D-aspartic acid; AMPA: a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; TARP: transmembrane AMPA receptor regulatory protein; ASD: autism spectrum disorder; CNV: copy number variation; IEG: immediately early gene; FRAP: fluorescence recovery after photobleaching; GKAP: guanylate kinase-associated protein; LRRTM: leucinerich repeat transmembrane protein; SALM: synaptic adhesion-like molecule; YFP: yellow fluorescent protein; CFP: cyan fluorescent protein.